• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The monoclonal antibodies react specifically with human interferon of the IFN-omega type but not with other human interferons.
    公开号:SU1602393A3
    申请号:SU874203388
    申请日:1987-09-29
    公开日:1990-10-23
    发明作者:Адольф Гюнтер
    申请人:Берингер Ингельгейм Интернациональ Гмбх (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to hybridoma technology and can be used in the preparation of monAT for interferon omega type.
    The method is carried out as follows.
    The splenic cells of an animal that has undergone a preliminary immunization with interferon such as omega or hybrid interferon, consisting of one part of interferon such as omega-1. and one part of interferon type alpha, preferably interferon type omega-1 or interferon types omega-1 and alpha-x and the subsequent additional immunization with interferon type omega, preferably interferon type omega-1, is subjected to fusion with myeloma cells, which preferably do not produce antibodies, for example, with myeloma cells of the P3X63Ag line 8,653.
    The resulting hybridoma cultures are screened to identify those clones that:: promote anti-interferon-type omega monoclonal antibodies (monAT). This goal, for example, will use biological experiments that can confirm
    ABOUT
    Yu
    with (: about with
    s
    Into the fyro received by PTTs 1TT.-1Liza tion of biological activities of interferon such as omega., for example, antiviral activity „
    From the cultures compressed according to the hgt method, which are designated as OIG-4, OMG-6, PMG-7 and OMG-8 - and which show a significant decrease in the antiviral activity of interLerone of omega-1 type, OMG-4 clones -5 and OMG-7, which are used for the production of monAT. For this purpose, selected hybridoma cell lines are cultured in vivo or in vitro. The cells of the selected clones are inoculated in a Balb / .c breed, which is pre-treated with Pristin or incomplete Freund da medium. After 7–18 days, an ascites fluid is collected, from which the monAT is injected by precipitation with ammonium sulfate and subsequent affine chromatography or other known methods. The resulting antibodies can also only be enriched in the insect fluid.
    The resulting antibody can be similarly enriched or isolated from the nozzle of the corresponding cell culture prepared in vitro. The monAT obtained by the method can be used not only to prove the presence of interlero type omega, but also to purify interferon like omega, preferably interferon like omega-1.
    If the monat produced is intended to finely purify interferon and omega, then it is preferably covalently bound to a biologically inactive carrier. In addition, the covalent bond of the antibody is carried out on a suitably activated carrier, preferably Hai dextro, based on, for example, cyan bromide or group CH sepharose. In this case, the interferon of the omega type, for example omega-1, should be cleaned in the form of a solution that is passed over the monAT obtained on a carrier at a low-axial pH value, for example at pH 7-8, preferably 7s, 5, and then washed at pH 7.5 to as long as glute no longer contains protein. The bound interferon is then eluted in the acidic region, for example, at P0.

    Ojl M relics of citric acid in 25% ethylene glycol. The resulting protein fractions thus obtained are subjected to chromatography on a strongly acidic cation exchanger, for example, on a mono-C cation exchanger. The human interferon in the eluate is immediately absorbed by the cation exchanger and then eluted with a sodium chloride gradient.
    If monAT is used as an antigen to prove the presence or for the quantitative determination of interferon such as omega, then well-known methods can be used using an immunosample.
    Example 1, Production of monoclonal antibodies specific for interferon such as omega.
    Immunization,
    A female of BaLb / c type, about eight weeks old, is immunized with highly purified (95% purity) hybrid interferon of the omega-1 / o62 type as follows. First immunization: 200 µg of the indicated interferon together with the complete Freund adjuvant (intrabryushchina), second immunization: 200 µm of the indicated interferon together with the full composition of the Freund supplement (intraperitoneally), the second immunization is carried out 5 weeks after the first immunization.
    0
    After eight weeks after the second immunization, the mouse is subjected to further immunization with 70 μg of purified interferon type omega-1 (purity 90%) using Freund's incomplete adjuvant (intraperitoneally). After 12 days, the forensic scientist shows that serum mince has relatively high titers of neutralizing antibodies against interferon such as omega-1 (complete neutralization upon dilution of serum up to 1000-fold, partial neutralization at 1000-fold dilution). The neutralization test is carried out as follows: 100 µg of a diluted serum sample in cell culture medium
    mixed with 100 µg of an inter- - feron solution of omega-1 type (100 antiviral units / mp) and incubated for 90 min. Then the antiviral activity of the samples is determined by a biological method using A549 cells of lung cancer infected with encephalitis myocarditis. 5 weeks after the third immunization, the mice again int 70 micrograms of purified interferon such as omega-1 (purity 90%) without supplementation.
    Hybrid screening and screening.
    Hybridoma production was carried out using non-segmented P3X63Ag8.653 cell lines. 4 days after the last immunization, the mouse spleen is taken; spleen cells are mechanically removed from tissue, suspended in cell culture medium (medium: RPMI 1640 with penicillin added as sodium salt; 100 units / ml) and streptomycin as sulfate salt (50 units / ml) and centrifuged for 10 minutes at 1000 rpm in Beckmann TI-6 type centrifuges. 2x1P myeloma cells (cultured in the above medium supplemented with 10% fetal bovine serum) are harvested by centrifugation and washed once with serum-free cell culture medium. Spleen cells and myeloma cells are then resuspended in serum-free cell culture medium, suspension. connect and re-centrifuge. Inadequate liquid is removed, the cells are suspended in 3 ml of medium 1.1, consisting of 45% RPMI 1640 medium, 50% polyethylene glycol with a molecular weight of 4000 and 5% dimethylsulfoxidine, and gently shake for 90 seconds. It is then left to stand for 60 s. 3 ml of the syringes without a mouthpiece of the medium are added dropwise over 90 seconds, the suspension is left to stand for 60 seconds, then further 6 ml of the 6ecciiiBopoTo4no4 nutrient medium are added dropwise within 90 seconds and, of course, constantly - reagi, slowly add 12 ml of nutrient medium with 10% EMPHOLIC bovine serum, leave to stand for 10 min and then bring to a volume of 50 ml by adding medium for cell culture with 10%
    1602393
    0
    fetal body serum. The cells are harvested by centrifugation, suspended in 40P ml of GAT medium (with 2 supplements of 20% fetal bovine serum, hypoxanthin 1,., Am1 nopterin 4x10 M and thymidine 1.6x10 M). To this suspension, peritoneal macrophages from 10 mice of breeds of 1 BaLb / c (approximately 50,000 cells / ml) are added.
    The suspension is pipetted to the plastic. There are small holes, each of which is equipped with 5 48 indentations (each recess has capacity 1; 0.5 ml). Plates are incubated at 37 ° C (95% air, 5% carbon dioxide, saturation.) With steam). After three days, 0.5 ml of HAT medium is added to each culture. Out of a total of 800 original cultures, after about 2-3 weeks, about 300 cultures show hybridoma cell growth. The subsequent screening of the sediment is as follows. Over sedimentary liquids, at least 10-20% of the fusion hybridoma cultures are mixed with the same volume of a solution of human inter- omega-1 type ferocides (20 antiviral units / mp), min at 37 s and then examined at least twice with a one week span. 5 out of 5 cultures, hereinafter referred to as OMG-4, OMG-5, OMG-6, OMG-7 and OMG-8, in all experiments always show a decrease in antiviral activity. All cultures are cloned by limiting dilution and the clones are again examined for neutralizing activity. From each culture, 3-5 positive clones are subjected to a distant0
    inefi processing. For sex cheni antibodies in vivo, 3-10x10 cells of each hybrid culture are intraperitoneally-1, but inoculated into Balb / c mice, which are injected three times a day with 0.5 m of incomplete Freyvda adjuvant or 7–10 days before this — 0.5 ml of adherence. After 7-21 days, the formed astc-gt liquid is collected. The antibodies contained in it are enriched to a purity higher than 90% by precipitating; 50% ammonium sulfate and a (chemical chromatography on carrier-linked protein A). For all hybridomas, about 2-5 mg are obtained for 1 ml of ascites fluid pure antibody.
    Characterization of antibodies OMG-4, OJIT-S and OMG-7.
    By polyacrylate gel electrophoresis using dodecyl sodium sulfate, carried out under non-reduced 1x conditions, and pressure gel chromatography, all antibodies show a retention characteristic identical to that of immunoglobulin R. In a neutralizer assay, in which inhibition of antiviral activity of 5 interferons is investigated, all antibodies at a concentration of 100 μg / ml neutralize the activity of interferon such as omega-1, but not the activity of interferon of the types lf-2c, beta and gamma. The above-indicated 2D clones were designated as non-viral with the numbers 87081404 (OMG-4), 87081402 (OMG-5) and 87081403 (OMG-7) in the European Collection of Animal Cell Cultures. Center for Applie d Micro- 5 biolof y and Research (UK). Example 2: Analysis using an enzyme-linked sample to determine inzo-terferon type omega-1.
    OMG-5 antibodies and OMG-7 are covalently bound to horseradish peroxidase. To do this, 2 ml of peroxidase in water -j are swept away with 0.2 ml of 100 mM sodium periodate, shaken at room temperature for 40 minutes and dialyzed at 4 ° C overnight at pH 4.4 using dO 2x500 ml 1 mM sodium attat. The solution is then adjusted to a pH of about 8 by the addition of 0.1 N sodium bicarbonate with a pH of 9.5. A solution is added to the solution, - thief. monoclonal antibodies (OMG-5, dz 2 ml with 1.6 mg / ml; or OMG-7, 1.5 ml with 4.7 mg / ml, each time in 10 mM sodium bicarbonate with a pH of 9.5), after Shake at room temperature for 2 hours. Add CQ 100 µl sodium borate solution (4 mg / ml feed) and incubate the solution in an ice bath for 2 hours. Then add 3 ml of cold saturated solution dropwise. ammonium sulphate solution and incubated on an ice bath. 1 hour. The precipitates associated with immunoglobulin peroxidase are collected by gingum 55

    s q
    five
    The fugitives are dissolved in a phosphate containing phosphate buffer with an isotonic saline solution with an EP of 7.4 and stabilized by adding t ml of cattle serum albumin solution (10 mg / ml in a phosphate buffer solution of saline). The resulting solution is frozen at minus 70 ° C.
    Determination of interferon type omega-1 using an enzyme-linked immunosample on a solid carrier is carried out as follows. Antibody OMG-2, OMG-5 or OMG-7 at a concentration of 10 µg / ml in 0.1 M sodium carbonate with a pI of 9.5 (100 µl per well) and the plates are incubated either at room temperature for an hour to coat the plates. , or at 4-8 ° C overnight. The antibody solution is removed, the wells are washed with 200 µl of water and filled with 100 µl of bovine serum albumin solution (5 mg / ml) in an isotonic saline solution with a pH of 7.4 (hereafter AC / PS solution) containing phosphate buffer. Then 100 µl of an interferon omega-1 type solution with a concentration of 20 ng / ml is added and mixed. Then, 50 µl of the solution associated with the antibody enzyme (OMG-5 / peroxidase or OMG-7 / peroxidase) (the solution is diluted in a ratio of 1: 10,000 in AC / PS) is fed into all the cavities and the plates are incubated at room temperature for 3 hours The solution is then removed, the wells are washed three times with water and filled with 100 µl of substrate solution (3 mg / ml o-phenylenediamine, 1 mg / ml sodium perborate in 0.067 M potassium nitrate, pH 5). After 30 min of incubation at room temperature, 100 µl of 4 N sulfuric acid is pipetted into each well, after which the optical density is measured at 492 nm. With all the samples tested (the antibody used to coat and the peroxylase-associated antibodies), a dose-dependent change in absorbance is achieved. To perform the coating, 10 µl / ml of immunoglobulin against interferon such as omega-1, obtained by immunizing rabbit twice with omega-1 type interferon and partially purifying from serum by precipitation with 50% sulfate, is also used.
    ammonium. An enzyme-assay assay can be used not only to quantify interferon such as omega-1, but also, for example, to determine the content of omega-1 type in cell-cell interferon or other interferon preparations obtained from cell cultures.
    PRI me R 3. Determination of interferon type by immunometry immunometry
    OMG-7 antibody is labeled with N-cc-scinimidyl (2.3 N) propionate (hereinafter: H-NCn: 110 Ci / mmol) using known methods. For this purpose, 1 mC1 of H-NCJI solution is dried in a siliconized container under vacuum.
    which is washed three times with 250 μl of water. Then 200 µl of the solution of the labeled antibody (100 ng / ml in AC / PS; per tube at about 27000 impulses / min) is added and incubated for 20 hours. Then the beads are washed three times with 20 µl of water, transferred into polypropylene tubes and added 4 mp scintillation medium, after which the bound radioactivity is measured. The use of the invention allows to obtain a monat of high specificity for interferon such as omega.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    Method for producing hybridoma, producing monoclonal antibodies
    Then, 50 µg of rast-2Q is added to the interferon type omega with a pipette, concluding with mont of Of ir-7 (4.7 mg / ml) in a buffer solution containing sodium chloride with a pH of 7.4 and 3 µl of 1 M borate buffer . RP 8.5. After 24 hours at 4 ° C, excess H-NCIT is removed by 25 to 20 µl of 1 M glygsh in borate buffer, diluted with 250 µl of 50 mM potassium phosphate buffer with a pH of 7.4j 150. m11 of sodium chloride and 5 mg / Mp albumin of bovine serum is separated from the labeled antibody by chromatography on a column (0.5x20 ms) containing Sephadex G 50 M, and the antibody shows specialty in that Mus.mus animal is culus L. subjected to double immunization with hybrid 1 # 1m interferon, consisting of 1 h of interferon such as omega-1 and 1 h, interferon of type o6-2 and then twice immunization with an omega-1-type interferon, the obtained immune cells of the spleen pre-cultured in serum cell culture medium, and the myeloma cells of the non-saccharine line RZHbZar, 8,653 are washed separately and suspended in serum-free cell culture medium.
    The physical activity of about 10 Ci / r 5 suspensions is combined with centriprotein. To carry out the experiment, etched polystyrene beads with a diameter of 6.5 mm were coated with OMG-2 antibody (10 µg / ml in O, 1 M sodium carbonate with a pH of 9.5; 1 hour at room temperature). The beads are fed to the AC / PS solution, incubated in tubes for one hour, and then washed twice with 250 μl of water. 200 µl of a 6-mega-1 type interferon solution is added to the beads at elevated concentrations of AC / PS, incubated at 4 ° C for 3 hours, after
    fugur, the pellet is suspended in medium containing 45% RPMI 1640, 50% polyethylene glycol and 5% dimethylsulfoxide, the suspension is shaken, the serum free serum is added to the culture, and then the medium with 10% fetal calf serum , centrifuged, the pellet suspended in medium with 20% fetal calf 45 serum, hypoxanthine, aminopterin and thymidine, mouse peritoneal macrophages are added to the suspension, incubated and the desired product is selected.
    p | 1is in that the animal Mus.mus-culus L. is subjected to double immunization with a hybrid of 1 to 1 m interferon, consisting of 1 h of interferon such as omega-1 and 1 h, interferon of type o6-2, and then twice immunization with interferon of omega type -1, the resulting immune cells of the spleen pre-cultured in the serum cell culture medium and the myeloma cells of the non-cervised RZHBZar line, 8,653 are washed separately and suspended in the serum-free cell culture medium.
    fugur, the pellet is suspended in medium containing 45% RPMI 1640, 50% polyethylene glycol and 5% dimethyl sulfone, the suspension is shaken, the serum-free cell culture medium is added, and then the medium with 10% fetal calf serum, centrifuged , the pellet is suspended in medium with 20% fetal bovine serum, hypoxanthine, aminopterin and thymidine, mouse peritoneal macrophages are added to the suspension, incubated and the desired product is selected.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0014519B1|1983-04-06|Cell lines, process for preparing them and process for producing antibodies
    KR920009496B1|1992-10-17|Method for obtaining novel colony stimulating factor
    CA1277261C|1990-12-04|Monoclonal antibodies and hybridoma cells, to humain reinin: processes for their preparation and their applications
    US5036003A|1991-07-30|Antibodies to VPF
    US4814275A|1989-03-21|Monoclonal hybridoma antibody specific for a human epithelial antigen
    US4863899A|1989-09-05|Biologically active polypeptides
    PT586002E|2000-07-31|MONOCLONAL ANTIBODIES RECOGNIZING THE EPIDERMIC GROWTH FACTOR RECEIVER, CELLS AND METHODS FOR ITS PRODUCTION AND COMPOSITIONS THAT INCLUDE THEM
    JPH06113832A|1994-04-26|Hybrid cell line for producing monoclonal antibody having high affinity for digoxin and its production
    US4558005A|1985-12-10|Monoclonal anti-erythropoietin
    EP0038642A1|1981-10-28|A monoclonal antibody against hepatitis B and its production, a hybridoma producing the monoclonal antibody and compositions containing it, the propagation of the hybridoma and the monoclonal antibody for use as an antiviral agent against hepatitus B and in isolating hepatitus b surface antigen from a sample
    SU1602393A3|1990-10-23|Method of producing hybridom producing monoclonal antibodies to interferon of omega tupe
    CA1296662C|1992-03-03|Hybridoma cell lines and their monoclonal antibodies to human pluripotent granulocyte colony stimulating factor
    EP0169234A1|1986-01-29|Immunoassay for biologically active human interferon-gamma.
    CA1337050C|1995-09-19|Monoclonal antibody selectively binding to novel g-csf derivative
    US4473493A|1984-09-25|Hybridoma antibody which inhibits interleukin 2 activity
    WO1986005188A1|1986-09-12|Monoclonal antibodies and assay
    KR940010021B1|1994-10-20|Monoclonal antibodies against atrial natriuretic peptides
    CA1330768C|1994-07-19|Monoclonal anti-human granulocyte colony stimulating factor antibody
    EP0043285B1|1984-01-04|Method for determination of valproic acid and reagents therein
    JP2888587B2|1999-05-10|Monoclonal antibody specific for cancer-related human galactosyltransferase, hybridoma producing the same, and method for measuring cancer-related human galactosyltransferase in a specimen using the same
    JP4493882B2|2010-06-30|Antigen and monoclonal antibody that distinguishes this antigen
    WO1987000182A1|1987-01-15|Monoclonal antibodies to gamma interferon, their production and use
    CA1276104C|1990-11-13|Method for determining human prolyl hydroxylase by radioimmunoassay
    JPH0659231B2|1994-08-10|Monoclonal antibody
    JP2948594B2|1999-09-13|Monoclonal antibody
    同族专利:
    公开号 | 公开日
    ZA877354B|1989-06-28|
    FI92716B|1994-09-15|
    KR960009724B1|1996-07-23|
    FI874273A0|1987-09-30|
    PH30662A|1997-09-16|
    DD269165A5|1989-06-21|
    NO173831B|1993-11-01|
    PT85830A|1987-10-01|
    IL84040D0|1988-02-29|
    NZ222006A|1990-08-28|
    NO173831C|1994-02-09|
    DK513687D0|1987-09-30|
    JPS63105673A|1988-05-10|
    ES2052534T3|1994-07-16|
    AT83262T|1992-12-15|
    GR3006846T3|1993-06-30|
    NO874107L|1988-04-05|
    AU616158B2|1991-10-24|
    KR880005258A|1988-06-28|
    EP0262571A3|1989-05-31|
    DE3633323A1|1988-04-07|
    DK172801B1|1999-07-26|
    JP2622260B2|1997-06-18|
    PT85830B|1990-07-31|
    DK513687A|1988-04-02|
    US5317089A|1994-05-31|
    NO874107D0|1987-09-30|
    FI92716C|1994-12-27|
    EP0262571B1|1992-12-09|
    CA1320160C|1993-07-13|
    IL84040A|1992-02-16|
    AU7921787A|1988-04-21|
    DE3783002D1|1993-01-21|
    IE59836B1|1994-04-06|
    IE872625L|1988-04-01|
    EP0262571A2|1988-04-06|
    HUT45092A|1988-05-30|
    FI874273A|1988-04-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EA013993B1|2004-06-16|2010-08-30|Верениум Корпорейшн|Compositions and methods for enzymatic de-colorization of chlorophyll|FI77877C|1979-04-20|1989-05-10|Technobiotic Ltd|Process for the preparation and purification of human Le-shaped interferon protein.|
    DE3306060A1|1983-02-22|1984-08-23|Boehringer Ingelheim International GmbH, 6507 Ingelheim|NEW IMMUNGLOBULIN-PRODUCING HYBRID CELL LINES, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF|
    DE3584198D1|1984-08-01|1991-10-31|Boehringer Ingelheim Int|NEW GENETIC SEQUENCES CODED BY TYPE I INTERFERON PEPTIDES AND THESE PRODUCING ORGANISMS.|
    EP0174143B1|1984-08-27|1989-11-08|Genentech, Inc.|Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor|
    DE3607835A1|1986-03-10|1987-09-24|Boehringer Ingelheim Int|HYBRID INTERFERONS, THEIR USE AS MEDICINAL PRODUCTS AND AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF ANTIBODIES AND THE USE THEREOF AND METHOD FOR THEIR PRODUCTION|DE3852166T2|1987-09-30|1995-04-06|Fujirebio Kk|Analytical device for enzyme immunological tests.|
    US7087726B2|2001-02-22|2006-08-08|Genentech, Inc.|Anti-interferon-α antibodies|
    CA2522345A1|2003-04-09|2004-11-18|Neose Technologies, Inc.|Glycopegylation methods and proteins/peptides produced by the methods|
    WO2011103164A1|2010-02-18|2011-08-25|Centocor Ortho Biotech Inc.|Monkey homolog of human interferon omega|
    CA2906526A1|2013-03-15|2014-09-25|Ellen Chi|Interferon alpha and omega antibody antagonists|
    TWI713453B|2014-06-23|2020-12-21|美商健生生物科技公司|Interferon alpha and omega antibody antagonists|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19863633323|DE3633323A1|1986-10-01|1986-10-01|NEW MONOCLONAL ANTIBODIES AGAINST IFN-OMEGA, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CLEANING AND DETECTING IFN-OMEGA|
    [返回顶部]